Maze Therapeutics
MAZE
68 hedge funds and large institutions have $441M invested in Maze Therapeutics in 2025 Q1 according to their latest regulatory filings, with 68 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
91.45% more ownership
Funds ownership: 0% → 91.45% (+91%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP IV
Boston,
Massachusetts
|
+$73.1M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$49.7M |
| 3 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$49.6M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$39.4M |
| 5 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$29.9M |
Top Sellers
MAZE Hedge Fund Activity: Q1 2025 in Review
68 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Maze Therapeutics (MAZE) for Q1 2025, worth a combined $441M.
Buyers outnumbered sellers: 68 funds opened new MAZE positions and 0 closed out — a net gain of 68 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TRV GP IV, opening a new position worth an estimated $73.1M.
- 68 institutional investors held Maze Therapeutics (MAZE) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $441M of Maze Therapeutics stock for Q1 2025.
- 68 funds opened new Maze Therapeutics positions in Q1 2025 and 0 closed out, a net change of +68 holders.
- The largest Maze Therapeutics buyer in Q1 2025 was TRV GP IV, an estimated $73.1M added.
Based on aggregated 13F filings for Q1 2025.